Elemy Exit Candidate

Employees 600+
Primary contact

🏦 Potential exit path: SPAC, IPO
Formerly known as Sprout Therapy, Elemy is a B2B2C platform for in-home pediatric behavioral care, including pediatric autism, ADHD, anxiety and more. The company works with Medicaid programs and insurance companies, leveraging technology to deliver a better experience to families, providers, and healthcare payors. Said technology is based around a model of care that Elemy describes as "integrated, evidence-based, and personalized."
Employees 600+
Primary contact

Funding πŸ’°

Total πŸ¦„ $323M
Last round πŸ”— $219M
Series B
October 6, 2021.
Select investors SoftBank Vision Fund, General Catalyst, Female Founders Fund, 8VC, Goodwater Capital, Sound Ventures, SignalFire, e.ventures, Amity Ventures

Key people πŸ§‘β€πŸ€β€πŸ§‘

Highlights ⭐

  • Big market: Just in the U.S. alone, Elemy estimates there are 1.8 million families with children with autism and, beyond that, one in five children have some sort of pediatric behavioral health need, according to the CDC. πŸ”—
  • The company on a mission: Elemy was founded to solve a "broken" system that can leave families waiting months or years to receive necessary (behavioral) care.
  • Exponential growth: Since launching in April 2020, Elemy has become one of the fastest-growing healthcare companies in the United States, scaling from 8 to over 800 employees in about 1.5 years.
  • Real impact: Elemy says its patients have reported an 83% reduction in problem behaviors and 88% increase in new skills, on average, after receiving care for at least six months.
  • "The company has the potential to improve the current standard of treatment for pediatric autism and deliver measurable outcomes. We have been impressed with the speed of Elemy’s growth and expansion since its launch." - Andrew Zloto, a SoftBank Investment Advisers director πŸ”—
Last update: February 21, 2022